A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson’s disease in which a patient’s stem cells are reprogrammed to replace dopamine cells in the brain. The first-of-its-kind clinical trial, based on more than three decades of research from McLean Hospital's Ole Isacson, has treated three-of-six participants who will be tracked for more than a year.

Just a few days of eating a diet high in saturated fat could be enough to cause memory problems and related brain inflammation in older adults, a new study in rats suggests.